SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 2 2025 08:45:03 提供 NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

04 2 2025 11:22:34 提供 NetDania Notify

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

04 2 2025 08:00:05 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 1 2025 08:45:48 提供 NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

28 1 2025 10:23:40 提供 NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

27 1 2025 09:40:08 提供 NetDania Notify

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

27 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

26 11 2024 16:00:18 提供 Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

13 11 2024 15:30:46 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 11 2024 08:45:03 提供 NetDania Notify

Supernus Announces Third Quarter 2024 Financial Results

04 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

31 10 2024 15:10:46 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 10 2024 14:07:03 提供 NetDania Notify

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

21 10 2024 15:25:48 提供 Nasdaq GlobeNewswire

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

17 10 2024 15:05:25 提供 Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

10 10 2024 16:12:14 提供 Nasdaq GlobeNewswire

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

24 9 2024 06:30:33 提供 Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

19 9 2024 15:30:44 提供 Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

28 8 2024 15:15:26 提供 Nasdaq GlobeNewswire

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

19 8 2024 06:00:51 提供 Nasdaq GlobeNewswire